Skip to main content
Links to homepage of ULTOMIRIS patient site

Call us at 1-877-GMG-ULTO (877-464-8586)

1; 0;

For adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive

ULTOMIRIS®IS

moving forward with
continuous symptom control*

Image is not of an actual patient

*Based on the Myasthenia Gravis Activities of Daily Living (MG-ADL). The MG-ADL is a scale that measures the impact of gMG symptoms on 8 key daily functions.
It is not known if ULTOMIRIS (ravulizumab-cwvz) is safe and effective for the treatment of gMG in children

ULTOMIRIS IS

The first and only long-acting C5 inhibitor

FDA approved to treat 4 rare autoimmune diseases, including anti-AChR antibody-positive gMG

Able to be taken with or without steroids

Discover continuous control over gMG symptoms†

See Study Results With ULTOMIRIS

The freedom of just 6-7 infusions per year, each lasting less than 1 hour‡

Explore Predictable Dosing

†Based on the Myasthenia Gravis Activities of Daily Living (MG-ADL). The MG-ADL is a scale that measures the impact of gMG symptoms on 8 key daily functions.

‡Once-every-8-week dosing, starting 2 weeks after an initial dose. Minimum infusion times for ULTOMIRIS 100 mg/mL maintenance doses range from 30 minutes to less than 1 hour, depending on body weight. If a side effect occurs during the infusion of ULTOMIRIS, the infusion may be slowed or stopped by the healthcare provider. After your infusion, your care team will monitor you for at least an additional hour for infusion-related reactions.

I was connected with OneSource, the Alexion Patient Support Team. They were so helpful in [getting me started on ULTOMIRIS].

Mike
Real ULTOMIRIS Patient

Mike, living with gMG, has received compensation from Alexion Pharmaceuticals, Inc.

Mike has a family member who is employed by Alexion, including at the time Mike started treatment.

Ask your doctor about managing your gMG symptoms with ULTOMIRIS

As measured by the Myasthenia Gravis Activities of Daily Living scale

Image is not of an actual patient

Download this helpful discussion guide full of information and ideas for talking to your doctor about ULTOMIRIS

Download The Doctor Discussion Guide

Questions? Call us at 1-877-GMG-ULTO (877-464-8586)

Receive information and updates

Stay Connected

Learn about support available through OneSource™, a free program offered by Alexion

Explore OneSource Support

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

What is the most important information I should know about ULTOMIRIS?
ULTOMIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.

  • ULTOMIRIS increases your chance of getting serious meningococcal infections that may quickly become life-threatening or cause death if not recognized and treated early.
  1. You must complete or update meningococcal vaccine(s) at least 2 weeks before your first dose of ULTOMIRIS.
  2. If you have not completed your meningococcal vaccines and ULTOMIRIS must be started right away, you should receive the required vaccine(s) as soon as possible.
  3. If you have not been vaccinated and ULTOMIRIS must be started right away, you should also receive antibiotics for as long as your healthcare provider tells you.
  4. If you had a meningococcal vaccine in the past, you might need additional vaccines before starting ULTOMIRIS. Your healthcare provider will decide if you need additional meningococcal vaccines.
  5. Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: fever, fever with high heart rate, headache and fever, confusion, muscle aches with flu-like symptoms, fever and a rash, headache with nausea or vomiting, headache with a stiff neck or stiff back, or eyes sensitive to light.

Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. Your risk of meningococcal infection may continue for several months after your last dose of ULTOMIRIS. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS and SOLIRIS Risk Evaluation and Mitigation Strategy (REMS). Before you can receive ULTOMIRIS, your healthcare provider must: enroll in the REMS program; counsel you about the risk of serious meningococcal infections; give you information about the signs and symptoms of serious meningococcal infection; make sure that you are vaccinated against serious infections caused by meningococcal bacteria, and that you receive antibiotics if you need to start ULTOMIRIS right away and are not up to date on your vaccines; give you a Patient Safety Card about your risk of meningococcal infection.

ULTOMIRIS may also increase the risk of other types of serious infections, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Certain people may be at risk of serious infections with gonorrhea.

Who should not receive ULTOMIRIS?
Do not receive ULTOMIRIS if you have a serious meningococcal infection when you are starting ULTOMIRIS.

Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

What are the possible side effects of ULTOMIRIS?
ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, abdominal pain, muscle spasms, changes in blood pressure, tiredness, feeling faint, shaking chills (rigors), discomfort in your arms or legs, bad taste, or drowsiness. Stop treatment of ULTOMIRIS and tell your healthcare provider right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion-related reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out.

The most common side effects of ULTOMIRIS in people with gMG are diarrhea and upper respiratory tract infections.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATION
What is ULTOMIRIS?
ULTOMIRIS is a prescription medicine used to treat adults with a disease called generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.

Please see the full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious meningococcal infections.

Questions? Call us at 1-877-GMG-ULTO (877-464-8586)